Corporate Update | October 2026

Neuritek Therapeutics remains focused on investigating mechanism-based approaches to post-traumatic stress disorder.

In March 2026, Neuritek entered into a nonbinding letter of intent with Wellgistics Health to explore a potential acquisition. Wellgistics subsequently disclosed on May 19, 2026, that it had terminated the letter of intent and would not proceed with the transaction.

Although this proposed transaction did not move forward, our commitment to advancing the science of PTSD remains. Our priorities are rigorous evaluation of the evidence, thoughtful clinical-development planning, and transparent communication with patients, collaborators, and stakeholders.

Read the May 19 disclosure.

Update 3/29/2026

Neuritek Therapeutics has entered into a Letter of Intent with Wellgistics Health Inc. to evaluate a potential strategic transaction. Further information will be shared as appropriate.

Neuritek Therapeutics Inc. is a biopharmaceutical company committed to developing revolutionary treatments with the potential to transform the lives of patients and families suffering from psychiatric disorders. Neuritek is developing the first mechanism-based treatment for Post-Traumatic Stress Disorder (PTSD).

• The IND for Phase 1 with the US FDA has cleared and the Phase 1 program has been successfully completed. Phase 2 PTSD is under preparation.

• Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers | Drugs in R&D

• Dysregulation of GPCRs plays a key role in PTSD and leads to novel PTSD therapeutic approaches

Reduce the risk, time and cost to bring next-generation bio mechanism based treatment, treating the root cause of PTSD, to market for people suffering from PTSD.